A5055725897- Colorectal Cancer Treatments and Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Neuroblastoma Research and Treatments
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Esophageal Cancer Research and Treatment
- Immune Cell Function and Interaction
- Cancer, Hypoxia, and Metabolism
- Renal cell carcinoma treatment
- Cancer Treatment and Pharmacology
- Cancer Diagnosis and Treatment
- Gallbladder and Bile Duct Disorders
- PARP inhibition in cancer therapy
- Liver Disease Diagnosis and Treatment
- Cancer Research and Treatments
- Immunotherapy and Immune Responses
- Cancer, Lipids, and Metabolism
- Cancer Mechanisms and Therapy
- Immune cells in cancer
Roswell Park Comprehensive Cancer Center
2016-2025
Teva Pharmaceuticals (United States)
2024
Sri Sathya Sai Institute of Higher Medical Sciences
2024
Apexigen (United States)
2023
Infinity Pharmaceuticals (United States)
2019-2023
Bristol-Myers Squibb (Germany)
2019-2023
Novartis (Switzerland)
2019-2023
Astellas Pharma (China)
2019-2023
Taiho Pharmaceutical (Japan)
2019-2023
AbbVie (United States)
2023
The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, cancer bile ducts (intrahepatic extrahepatic cholangiocarcinoma). Due to multiple modalities that can be used treat disease complications arise from comorbid liver dysfunction, a multidisciplinary evaluation is essential determining an optimal treatment strategy. A team should include hepatologists, diagnostic radiologists,...
To develop an evidence-based clinical practice guideline to assist in decision making for patients with advanced hepatocellular carcinoma (HCC).
The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations cancers of the liver, gallbladder, and bile ducts. Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data publications abstracts, reevaluate update recommendations. These Insights summarize panel's discussion most recent regarding locoregional therapy patients with hepatocellular carcinoma.
Abstract The extent to which T-cell–mediated immune surveillance is impaired in human cancer remains a question of major importance, given its potential impact on the development generalized treatments advanced disease where highest degree heterogeneity exists. Here, we report first global analysis dysfunction patients with hepatocellular carcinoma (HCC). Using multi-parameter fluorescence-activated cell sorting analysis, quantified cumulative frequency regulatory T cells (Treg), exhausted...
The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations cancers of the liver, gallbladder, and bile ducts. Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data publications abstracts, reevaluate update recommendations. These Insights summarize panel’s discussion updated regarding systemic therapy first-line subsequent-line patients with hepatocellular carcinoma.
In 2023, the NCCN Guidelines for Hepatobiliary Cancers were divided into 2 separate guidelines: Hepatocellular Carcinoma and Biliary Tract Cancers. The provide recommendations evaluation comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma. multidisciplinary panel experts meets at least on an annual basis to review requests from internal external entities as well evaluate new data current emerging therapies. These Insights...
LBA490 Background: Biliary tract cancers (BTCs) are a heterogeneous group of malignancies with dismal prognosis. Gemcitabine-based regimens the standard care in advanced disease, but median overall survival (OS) is roughly 12 months. The addition albumin-bound paclitaxel to gemcitabine and cisplatin (GAP) demonstrated promising efficacy 60 patient, single-arm phase II study (Shroff et al, JAMA Oncol 2019), observed OS 19.2 Methods: SWOG 1815 randomized, open-label, III trial comparing GAP...
To update an evidence-based guideline to assist in clinical decision-making for patients with advanced hepatocellular carcinoma (HCC).
Hepatobiliary cancers include a spectrum of invasive carcinomas arising in the liver (hepatocellular carcinoma), gall bladder, and bile ducts (cholangiocarcinomas). Gallbladder cancer cholangiocarcinomas are collectively known as biliary tract cancers. is most common aggressive type all Cholangiocarcinomas diagnosed throughout tree typically classified either intrahepatic or extrahepatic cholangiocarcinoma. Extrahepatic more than cholangiocarcinomas. This manuscript focuses on clinical...
Objectives: Vascular endothelial growth factor overexpression, seen in 42% to 76% of biliary tract cancers (BTCs), correlates with poor survival. We explored the safety/efficacy and potential biomarkers for bevacizumab combination gemcitabine-capecitabine advanced BTCs. Patients Methods: Inoperable stage III/IV BTC patients our prospective study were given 1000 mg/m 2 gemcitabine (on days 1, 8), 650 capecitabine 1 14), 15 mg/kg day 1) 21-day cycles. Circulating tumor cells quality life...
Sorafenib is an oral antiangiogenic agent administered in advanced-stage hepatocellular carcinoma (HCC). Based on preclinical and human studies, we hypothesized that, addition to its properties, sorafenib may beneficially reduce the extent of immunosuppressive network HCC patients. To test this hypothesis, examined whether alterations burden patients correlated with clinical outcome.In before after treatment, blood samples collected from 19 advanced HCC, frequency PD-1+ T cells, Tregs,...
BACKGROUNDSorafenib has been shown to reduce the extent of immunosuppression in patients with hepatocellular carcinoma (HCC). The rationale this investigation was identify biomarkers that can predict treatment efficacy sorafenib HCC and unravel mechanism by which impedes immune suppression mediated distinct immunosuppressive cell subsets.METHODSWith informed consent, blood samples were collected from 30 advanced HCC, at baseline 2 time points after initiation treatment. frequency PD-1+ T...
Gastrointestinal (GI) cancers, including esophageal, gastroesophageal junction, gastric, duodenal and distal small bowel, biliary tract, pancreatic, colon, rectal, anal cancer, comprise a heterogeneous group of malignancies that impose significant global burden. Immunotherapy has transformed the treatment landscape for several GI offering some patients durable responses prolonged survival. Specifically, immune checkpoint inhibitors (ICIs) directed against programmed cell death protein 1...
The tumor-suppressor p53 is commonly inactivated in colorectal cancer and pancreatic ductal adenocarcinoma, but existing treatment options for p53-mutant (p53
The incidence of gemcitabine-induced hemolytic uremic syndrome (GiHUS) has been reported to be between 0.02% and 2.2% (1,2). A variety therapies have employed in the treatment GiHUS with varying success. In some cases discontinuation drug will result remission HUS (3). benefit plasmapheresis atypical forms (aHUS) such as questioned (4). Other modalities used rates success including high dose corticosteroids, vincristine, rituximab (3,5). Eculizumab is a monoclonal antibody directed against...